• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Pharmaceutical Market
    Pharmaceutical News
    Pharmaceutical Stocks
    • Pharmaceutical Market
    • Pharmaceutical News
    • Pharmaceutical Stocks
    pharmaceutical investing

    Merck’s KEYTRUDA (pembrolizumab) Demonstrated Long-Term Survival Benefit Based on Four and Five Years of Follow-Up from Two Pivotal Studies in Advanced Melanoma

    Gabrielle Lakusta
    Jun. 04, 2018 09:22AM PST
    Pharmaceutical Investing

    Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced long-term efficacy data from the Phase 3 KEYNOTE-006 study and the melanoma cohort of the Phase 1b KEYNOTE-001 study investigating KEYTRUDA, Merck’s anti-PD-1 therapy, in patients with advanced melanoma. As quoted in the press release: “Looking across the findings for both KEYNOTE-006 …

    Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced long-term efficacy data from the Phase 3 KEYNOTE-006 study and the melanoma cohort of the Phase 1b KEYNOTE-001 study investigating KEYTRUDA, Merck’s anti-PD-1 therapy, in patients with advanced melanoma.

    As quoted in the press release:

    “Looking across the findings for both KEYNOTE-006 and KEYNOTE-001 we are seeing further validation that KEYTRUDA is significantly extending the survival of first-line metastatic melanoma patients, regardless of tumor BRAF-mutation status,” said Scot Ebbinghaus, M.D., vice president, clinical research, Merck Research Laboratories. “In KEYNOTE-006, we are also seeing durable efficacy benefits for patients who complete two years of KEYTRUDA treatment. We are pleased to share data that further reinforce KEYTRUDA monotherapy as a standard of care in advanced melanoma patients and deliver on our goal of improving and extending the lives of melanoma patients.”

    “Pembrolizumab had already established superior survival outcomes versus ipilimumab in advanced melanoma patients, and this is further reinforced with four years of data in KEYNOTE-006,” said Professor Georgina V. Long, conjoint medical director of Melanoma Institute Australia (MIA), and chair of Melanoma Medical Oncology and Translational Research at MIA and Royal North Shore Hospital, The University of Sydney. “Importantly, we’re now seeing ongoing efficacy for patients who complete the protocol-specified two years of pembrolizumab treatment, as well as additional anti-tumor activity for the patients who progress after a first course of treatment and complete a second course of treatment.”

    Click here to read the full press release.

    pharmaceutical investing
    The Conversation (0)

    Go Deeper

    AI Powered
    Amplia Therapeutics

    Tumour Response in Sixth Patient Triggers Additional Recruitment in Pancreatic Cancer Trial

    AbbVie Features New Data Across Difficult-to-Treat Solid Tumors and Blood Cancers at ASCO 2025, Highlighting Breadth and Depth of its Oncology Portfolio

    AbbVie Features New Data Across Difficult-to-Treat Solid Tumors and Blood Cancers at ASCO 2025, Highlighting Breadth and Depth of its Oncology Portfolio

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Pharmaceutical Investing Stocks

    Invion Limited

    IVX:AU

    Cardiol Therapeutics

    CRDL:CA
    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×